Price T Rowe Associates Inc Viridian Therapeutics, Inc.\De Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Price T Rowe Associates Inc holds 45,012 shares of VRDN stock, worth $875,483. This represents 0.0% of its overall portfolio holdings.
Number of Shares
45,012
Previous 44,419
1.34%
Holding current value
$875,483
Previous $578,000
77.34%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding VRDN
# of Institutions
178Shares Held
76.6MCall Options Held
581KPut Options Held
439K-
Black Rock Inc. New York, NY4.77MShares$92.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$86 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$75.5 Million9.15% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.75MShares$73 Million3.15% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.45MShares$67 Million12.74% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $776M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...